Artelo Biosciences, Inc. (ARTL) Press Releases https://ir.artelobio.com/news-events/press-releases/rss en-us https://d1io3yog0oux5.cloudfront.net/artelobio/files/theme/images/logo-sm.png Artelo Biosciences, Inc. Logo Equisolve Investor Relations Suite <![CDATA[Artelo Biosciences Files New Provisional Patent Application Covering ART27.13 for Obesity, Alone and in Combination with GLP-1 Receptor Agonists, Following Unexpected Nonclinical Findings]]> https://ir.artelobio.com/news-events/press-releases/detail/203/artelo-biosciences-files-new-provisional-patent-application Wed, 23 Sep 26 07:33:00 -0400 https://ir.artelobio.com/news-events/press-releases/detail/203/artelo-biosciences-files-new-provisional-patent-application <![CDATA[Artelo Biosciences Announces ART27.13 Achieved Weight Loss Comparable to Semaglutide as a Monotherapy and Doubled Weight Loss in Combination with Semaglutide in a Nonclinical Model of Obesity]]> https://ir.artelobio.com/news-events/press-releases/detail/202/artelo-biosciences-announces-art27-13-achieved-weight-loss Wed, 16 Sep 26 07:30:00 -0400 https://ir.artelobio.com/news-events/press-releases/detail/202/artelo-biosciences-announces-art27-13-achieved-weight-loss <![CDATA[Artelo Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference]]> https://ir.artelobio.com/news-events/press-releases/detail/201/artelo-biosciences-to-present-at-the-h-c-wainwright-28th Tue, 08 Sep 26 09:00:00 -0400 https://ir.artelobio.com/news-events/press-releases/detail/201/artelo-biosciences-to-present-at-the-h-c-wainwright-28th <![CDATA[Artelo Biosciences Announces Reverse Stock Split]]> https://ir.artelobio.com/news-events/press-releases/detail/200/artelo-biosciences-announces-reverse-stock-split Thu, 27 Aug 26 08:00:00 -0400 https://ir.artelobio.com/news-events/press-releases/detail/200/artelo-biosciences-announces-reverse-stock-split <![CDATA[Artelo Biosciences Secures Notice of Allowance in Japan for Patent Claims for the Intended Commercial Formulation of ART27.13]]> https://ir.artelobio.com/news-events/press-releases/detail/199/artelo-biosciences-secures-notice-of-allowance-in-japan-for Thu, 20 Aug 26 08:52:00 -0400 https://ir.artelobio.com/news-events/press-releases/detail/199/artelo-biosciences-secures-notice-of-allowance-in-japan-for <![CDATA[Artelo Biosciences Receives a Notice of Allowance from the U.S. Patent and Trademark Office for its Lead Investigational Drug Currently in Two Phase 2 Studies]]> https://ir.artelobio.com/news-events/press-releases/detail/198/artelo-biosciences-receives-a-notice-of-allowance-from-the Mon, 17 Aug 26 08:52:00 -0400 https://ir.artelobio.com/news-events/press-releases/detail/198/artelo-biosciences-receives-a-notice-of-allowance-from-the <![CDATA[Artelo Biosciences Provides Business Update and Reports 2026 Second Quarter Financial Results]]> https://ir.artelobio.com/news-events/press-releases/detail/197/artelo-biosciences-provides-business-update-and-reports Thu, 13 Aug 26 08:00:00 -0400 https://ir.artelobio.com/news-events/press-releases/detail/197/artelo-biosciences-provides-business-update-and-reports <![CDATA[Artelo Announces Enrollment of First Patient in a Phase 2 Clinical Trial Evaluating ART27.13 for Treatment of Glaucoma]]> https://ir.artelobio.com/news-events/press-releases/detail/196/artelo-announces-enrollment-of-first-patient-in-a-phase-2 Mon, 10 Aug 26 08:47:00 -0400 https://ir.artelobio.com/news-events/press-releases/detail/196/artelo-announces-enrollment-of-first-patient-in-a-phase-2 <![CDATA[New Analysis of Over 50 Studies Showed that All the Non-Prescription CBD Products Researched Fell Short of Therapeutic Efficacy — Reinforcing the Case for Artelo's Optimized ART12.11 CBD Composition]]> https://ir.artelobio.com/news-events/press-releases/detail/195/new-analysis-of-over-50-studies-showed-that-all-the Wed, 22 Jul 26 08:39:00 -0400 https://ir.artelobio.com/news-events/press-releases/detail/195/new-analysis-of-over-50-studies-showed-that-all-the <![CDATA[Artelo Biosciences Announces Results from a Nonclinical Osteoarthritis Study Supporting ART26.12 as a Potential First-in-Class New Therapy for Chronic Pain Conditions]]> https://ir.artelobio.com/news-events/press-releases/detail/194/artelo-biosciences-announces-results-from-a-nonclinical Thu, 16 Jul 26 08:48:00 -0400 https://ir.artelobio.com/news-events/press-releases/detail/194/artelo-biosciences-announces-results-from-a-nonclinical